Holen Sie sich die Stockscreener-App
1.55
1.31%
0.02
Handel nachbörslich:
1.57
0.02
+1.29%
Schlusskurs vom Vortag:
$1.53
Offen:
$1.48
24-Stunden-Volumen:
247.49K
Relative Volume:
0.93
Marktkapitalisierung:
$46.61M
Einnahmen:
$210.70K
Nettoeinkommen (Verlust:
$-21.37M
KGV:
-1.4091
EPS:
-1.1
Netto-Cashflow:
$-21.10M
1W Leistung:
+0.32%
1M Leistung:
-10.40%
6M Leistung:
-39.45%
1J Leistung:
+65.58%
1-Tages-Spanne:
$1.48
$1.64
1-Wochen-Bereich:
$1.45
$1.64
52-Wochen-Spanne:
$0.95
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Firmenname
Gain Therapeutics Inc
Sektor
Branche
Telefon
(301) 500-1556
Adresse
4800 HAMPDEN LANE, BETHESDA
Vergleichen Sie GANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.55 | 52.89M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-08-14 | Fortgesetzt | Oppenheimer | Outperform |
| 2021-04-12 | Eingeleitet | BTIG Research | Buy |
| 2021-04-12 | Eingeleitet | Oppenheimer | Outperform |
Gain Therapeutics Inc Aktie (GANX) Neueste Nachrichten
Intraday Charts Show Spike in Gain Therapeutics Inc. ActivityBond Market & Smart Swing Trading Alerts - 선데이타임즈
Is Gain Therapeutics Inc. forming a reversal patternPortfolio Gains Summary & Growth Focused Entry Point Reports - Newser
Has Gain Therapeutics Inc. found a price floorWeekly Investment Report & Community Trade Idea Sharing - Newser
Candlestick signals on Gain Therapeutics Inc. stock today [Market Weekly Review]Safe Swing Trade Setup Alerts - Newser
What analysts say about Gain Therapeutics Inc. stock outlookMarket Activity Report & Daily Profit Focused Screening - Newser
What analysts say about Gain Therapeutics Inc. stock outlook [2025 Market Sentiment]High Accuracy Investment Signals - Newser
Gain Therapeutics Inc.’s Price Action Aligns with Quant SignalsReal-Time Analysis With Entry Targets In Progress - 선데이타임즈
Gain Therapeutics Fast-Tracks Parkinson's Drug Trial: Key Results Coming Q4 2025, Raises $7.1M - Stock Titan
Gain Therapeutics GANX 2025Q2 Earnings Preview Upside Potential on Robust Revenue Growth - AInvest
Using flow based indicators on Gain Therapeutics Inc.Low Risk High Confidence Watchlist Builder - Newser
Analyzing recovery setups for Gain Therapeutics Inc. investorsTrade Safety Report with Pattern Insights - Newser
Healthcare Stocks in Focus: Gainers and Losers in Friday's After-Market Session - AInvest
Why Gain Therapeutics Inc. stock attracts strong analyst attentionFree Safe Entry Stock Watch Suggestions - Newser
Visualizing Gain Therapeutics Inc. stock with heatmapsConsistent Return Setup with Exit Strategy - Newser
Best data tools to analyze Gain Therapeutics Inc. stockGrowth Watchlist for Long Term Positioning - Newser
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Average Target Price from Analysts - Defense World
Gain Therapeutics (GANX) Projected to Post Earnings on Thursday - Defense World
What makes Gain Therapeutics Inc. stock price move sharplyGrowth Summary Based on Market Positioning - Newser
Candlestick signals on Gain Therapeutics Inc. stock todayMarket Stability and Long-Term Growth Outlook - Newser
Gain Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
What technical models suggest about Alaunos Therapeutics Inc.’s comebackWeekly Signal Report with Trend Summary - Newser
What is the dividend policy of Gain Therapeutics Inc. stockConsistent wealth multiplication - Jammu Links News
Should I hold or sell Gain Therapeutics Inc. stock in 2025Discover breakthrough investment opportunities - Jammu Links News
Is Gain Therapeutics Inc. a good long term investmentAchieve breakthrough financial results today - Jammu Links News
Is Gain Therapeutics Inc. stock overvalued or undervaluedMaximize returns with disciplined trading approaches - Jammu Links News
What catalysts could drive Gain Therapeutics Inc. stock higher in 2025Capitalize on high-yield stocks early - Jammu Links News
Evaluating Gain Therapeutics Inc. with trendline analysisPortfolio Review Summary with Five-Year Outlook - Newser
What are analysts’ price targets for Gain Therapeutics Inc. in the next 12 monthsHigh-velocity gains - Jammu Links News
How does Gain Therapeutics Inc. compare to its industry peersAccelerated capital growth - Jammu Links News
How does Gain Therapeutics Inc. generate profit in a changing economyConsistent triple returns - Jammu Links News
What are the latest earnings results for Gain Therapeutics Inc.Free Bull & Bear Market Updates - Jammu Links News
Finanzdaten der Gain Therapeutics Inc-Aktie (GANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):